Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option Exercises and Stock Sales
SEC Form 4 Filing
Enliven Therapeutics' CFO, Benjamin Hohl, executed option exercises and subsequent stock sales under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Benjamin Hohl, the CFO of Enliven Therapeutics, executed option exercises and sales of common stock on September 27, 2024, and September 30, 2024.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
- On September 27, 2024, Hohl exercised options to acquire 4,250 shares at $2.48 per share and then sold those shares at a weighted average price of $24.2732.
- On September 30, 2024, Hohl exercised options to acquire 2,000 shares at $2.48 per share and then sold those shares at a weighted average price of $25.3338.
- Following these transactions, Hohl directly owns 192,879 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a pre-arranged 10b5-1 trading plan suggests the transactions were planned in advance to avoid accusations of insider trading.
Comparison to Industry Standards
- Comparing the CFO's trading activity to similar transactions by executives at comparable biotech companies can provide context.
- For example, if other CFOs in the biotech sector are also exercising options and selling shares, it might indicate a broader trend related to executive compensation or market conditions.
- However, without specific data on peer companies, it's difficult to draw definitive conclusions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the number of shares available in the market.
- However, given the relatively small number of shares involved, the impact is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 2022-08-02 | Initial vesting date for one-fourth of the stock options. |
| 2023-06-26 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2024-08-02 | Expiration date of the stock options. |
| 2024-09-27 | Date of first reported transaction: option exercise and sale of 4,250 shares. |
| 2024-09-30 | Date of second reported transaction: option exercise and sale of 2,000 shares. |
| 2024-10-01 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.